CO ameliorates endothelial senescence induced by 5-fluorouracil through SIRT1 activation

Arch Biochem Biophys. 2019 Nov 30:677:108185. doi: 10.1016/j.abb.2019.108185. Epub 2019 Nov 5.

Abstract

Endothelial senescence is the main risk factor that contributes to vascular dysfunction and the progression of vascular disease. Carbon monoxide (CO) plays an important role in preventing vascular dysfunction and in maintaining vascular physiology or homeostasis. The application of exogenous CO has been shown to confer protection in several models of cardiovascular injury or disease, including hypertension, atherosclerosis, balloon-catheter injury, and graft rejection. However, the mechanism by which CO prevents endothelial senescence has been largely unexplored. The aim of this study was to evaluate the effects of CO on endothelial senescence and to investigate the possible mechanisms underlying this process. We measured the levels of senescence-associated-β-galactosidase activity, senescence-associated secretory phenotype, reactive oxygen species (ROS) production, and stress granule in human umbilical vein endothelial cells and the WI-38 human diploid fibroblast cell line. We found that 5-fluorouracil (5FU)-induced ROS generation was inhibited by CO-releasing molecules (CORM)-A1 treatment, and endothelial senescence induced by 5FU was attenuated by CORM-A1 treatment. The SIRT1 inhibitor EX527 reversed the inhibitory effect of CO on the 5FU-induced endothelial senescence. Furthermore, SIRT1 deficiency abolished the stress granule formation by CO. Our results suggest that CO alleviates the endothelial senescence induced by 5FU through SIRT1 activation and may hence have therapeutic potential for the treatment of vascular diseases.

Keywords: 5-Fluorouracil; Carbon monoxide; Endothelial senescence; Reactive oxygen species; SIRT1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antioxidants / pharmacology
  • Carbon Monoxide / pharmacology*
  • Cellular Senescence / drug effects*
  • Down-Regulation
  • Fluorouracil / pharmacology*
  • Heme Oxygenase-1 / metabolism
  • Human Umbilical Vein Endothelial Cells / drug effects*
  • Human Umbilical Vein Endothelial Cells / pathology
  • Humans
  • Nitric Oxide Synthase Type III / metabolism
  • Reactive Oxygen Species / metabolism
  • Sirtuin 1 / metabolism*

Substances

  • Antioxidants
  • Reactive Oxygen Species
  • Carbon Monoxide
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • HMOX1 protein, human
  • Heme Oxygenase-1
  • SIRT1 protein, human
  • Sirtuin 1
  • Fluorouracil